GlassScriptPhysician profile
Larry K Broadwell
NPI 1326194036
$32,920.99
in general payments reported to CMS, 2019-2025
41 companies · $3,497 in 2025
The $3,497 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,993 · 2020: $3,878 · 2021: $4,664 · 2022: $5,340 · 2023: $4,498 · 2024: $5,051 · 2025: $3,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,747.25 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $8,482.62 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $5,533.91 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $2,516.61 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $2,131.94 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $2,118.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,888.44 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,656.49 | 2019-2025 | |
| Lilly USA, LLC | $1,044.85 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $992.43 | 2021-2025 | Acthar |
| Genentech USA, INC. | $983.27 | 2019-2023 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $795.30 | 2019-2025 | Orencia |
| Radius Health, INC. | $486.03 | 2019-2023 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $476.83 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $432.63 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.65 | 2021-2025 | Cyltezo, Ofev |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $385.12 | 2021-2025 | Saphnelo, Evusheld |
| Ani Pharmaceuticals, INC. | $379.37 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $370.70 | 2019-2023 | Krystexxa, Tepezza |
| Genzyme Corporation | $314.41 | 2020-2025 | |
| Pacira Therapeutics, INC. | $145.81 | 2019-2021 | |
| Celgene Corporation | $142.71 | 2019 | |
| Scilex Pharmaceuticals INC. | $137.64 | 2024 | |
| Organon LLC | $129.26 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Fresenius Kabi USA, LLC | $121.68 | 2023-2024 | Idacio |
| US Oncology Corporate, INC. | $119.87 | 2024 | |
| Genentech, INC. | $117.13 | 2021 | |
| Gilead Sciences, INC. | $101.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $88.16 | 2020-2024 | Truxima |
| Mallinckrodt Enterprises LLC | $76.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $62.40 | 2024-2025 | Opsumit |
| Alexion Pharmaceuticals, INC. | $58.73 | 2020-2024 | Strensiq |
| Antares Pharma, INC. | $37.59 | 2019-2020 | |
| Invivyd INC | $28.46 | 2025 | Pemgarda |
| Medexus Pharma, INC. | $22.25 | 2019 | |
| Alvogen INC | $21.22 | 2025 | Teriparatide |
| Almatica Pharma LLC | $20.60 | 2024 | Teriparatide |
| Kyowa Kirin, INC. | $17.34 | 2024 | Crysvita |
| Kiniksa Pharmaceuticals, LTD. | $16.97 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.93 | 2024 | Arcalyst |
| Avion Pharmaceuticals | $14.01 | 2020 | |
| Sobi, INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Broadwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.